
A curated selection of the top stories and editor’s picks from the DocWire News Cardiology section over the last week.
ODYSSEY OUTCOMES: Alirocumab Lowers Second Heart Attack Risk
The full results of the ODYSSEY OUTCOMES study, looking at PCSK9 inhibitor alirocumab for the reduction of second heart attack risk in patients who had survived a first heart attack.